Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR2E1 | Q9Y466 | 8/20 | 0.51 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 8/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.50 |
| ▸ | TNNI3K | Q59H18 | 2/20 | 0.50 |
| ▸ | BRAF | P15056 | 1/20 | 0.50 |
| ▸ | LDLR | P01130 | 1/20 | 0.49 |
| ▸ | KIT | P10721 | 1/20 | 0.49 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.49 |
| ▸ | RAF1 | P04049 | 1/20 | 0.48 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5335173 | 0.86 | KDR (0.59) | KDRMAPK14TNNI3KBRAFRAF1 | |
| SCHEMBL22528802 | 0.83 | KDR (0.66) | NR2E1MAP4K2KDRMAPK14TNNI3K | |
| SCHEMBL827379 | 0.82 | NTRK1 (0.52) | NR2E1KDRMAPK14TNNI3KBRAF | |
| SCHEMBL828849 | 0.81 | KDR (0.54) | NR2E1KDRBRAFLDLRKIT | |
| SCHEMBL574372 | 0.81 | CSF1R (0.58) | KDRBRAF | |
| SCHEMBL573468 | 0.81 | KDR (0.54) | NR2E1KDRBRAFLDLRKIT | |
| SCHEMBL22528864 | 0.80 | KDR (0.66) | NR2E1MAP4K2KDRMAPK14TNNI3K | |
| SCHEMBL5349430 | 0.79 | NTRK1 (0.67) | MAP4K2KDRMAPK14TNNI3KBRAF | |
| SCHEMBL5450727 | 0.78 | KDR (0.53) | KDRMAPK14TNNI3KBRAFRAF1 | |
| SCHEMBL5460315 | 0.78 | KDR (0.77) | KDRBRAFKITRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070155764-A1 | NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES | KALYPSYS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070155764-A1 | NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES | KALYPSYS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155764-A1 | NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES | BRAF, ARAF, RAF1 | NR2E1 2468/4885MAP4K2 13/4885KDR 555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.